Alla studier
RekryteringFAS3INTERVENTIONELL

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

Researchers are exploring new treatments for advanced ovarian cancer. After initial surgery and chemotherapy, many women receive maintenance treatment to prevent the cancer from returning or growing. This study is testing if a new targeted therapy, called sacituzumab tirumotecan (sac-TMT), either alone or with another standard drug called bevacizumab, can extend the time before the cancer worsens. This is compared to current standard care options, which include bevacizumab maintenance or close observation. The aim is to find out if sac-TMT can help women live longer without their cancer progressing, for those whose cancer has responded well to their first round of treatment.

Överblick

Status
Rekrytering
Fas
FAS3
Sponsor
Merck Sharp & Dohme LLC
Inskrivningsmål
900
Starta
16 feb 2026
Beräknad slutförande
25 Feb 2033

Vad handlar denna studie om?

When someone is diagnosed with ovarian cancer, doctors often try to remove as much of the cancer as possible with surgery. After surgery, chemotherapy is typically given to kill any remaining cancer cells. The next step is often to keep the cancer from coming back or growing, and this is where this study comes in.

Currently, after chemotherapy, some people receive maintenance treatment, which is like a protective shield designed to keep the cancer at bay. Bevacizumab is a common maintenance drug. Other times, doctors might just keep a close eye on the cancer with regular check-ups. This study is trying to understand if a new medicine, called sacituzumab tirumotecan (sac-TMT), can be a better maintenance treatment.

Sac-TMT is a type of targeted therapy, which means it's designed to specifically attack cancer cells while trying to leave healthy cells alone. The main goal of this research is to see if giving sac-TMT, either by itself or along with bevacizumab, helps women with ovarian cancer live longer without their cancer getting worse, compared to the usual treatments. This is especially for women whose cancer has responded well to their first set of treatments.

Viktiga punkter

  • This study is testing a new drug for advanced ovarian cancer after initial treatment.
  • It aims to see if sac-TMT (a targeted therapy) can keep cancer from worsening longer.
  • Participation involves receiving either the new drug or standard care, assigned by chance.
  • This is a Phase 3 trial, meaning it's a large study comparing the new treatment to existing ones.
  • It's for women whose cancer responded well to their first round of chemotherapy.
  • Du har rätt att lämna studien när som helst.

Vem kan vara berättigad?

This study is looking for women who have advanced ovarian cancer, or similar cancers of the fallopian tube or peritoneum, that has been confirmed by a doctor. You would need to have already had surgery and completed your first course of chemotherapy, and your cancer should have responded well to that treatment – meaning it’s stable, partly gone, completely gone, or not detectable.

There are also some important health checks. For example, if you have HIV, it needs to be well-controlled. Similar rules apply if you have hepatitis B or C – these conditions need to be managed and not active. You would also need to provide a sample of your tumor tissue that hasn't been treated with radiation before.

However, there are reasons why you might not be able to join. For instance, if your cancer is a very specific type (like certain low-grade or borderline tumors), or if you have cancer that has spread to your brain or spinal cord. Other health conditions like severe eye disease, active inflammatory bowel disease needing strong medication, or serious, uncontrolled heart or blood vessel problems would also prevent you from taking part. You also can’t have had systemic cancer treatment (other than your initial chemotherapy) or certain vaccinations recently, or another type of active cancer or serious infection.

Kan denna studie passa dig?

Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.

  1. Have I been diagnosed with advanced ovarian, fallopian tube, or peritoneal cancer?
  2. Have I completed surgery and my first course of platinum-based chemotherapy?
  3. Has my cancer responded well to my first chemotherapy (stable, getting better, or undetectable)?
  4. Do I have any other serious uncontrolled health conditions like heart problems or active inflammatory bowel disease?
  5. Do I have any cancer spread to my brain or spinal cord?
  6. Am I over 18 years old and female?
Svara på varje fråga för att se ditt resultat.

Vad innebär deltagande?

If you decide to take part in this study, you would first go through a screening process to make sure the study is right for you. This might involve additional hospital visits, more tests, and discussions with the study team. Once enrolled, you would receive either the study medicine (sac-TMT, with or without bevacizumab) or standard care, which could be bevacizumab or observation, depending on which group you are assigned to. This is done by chance, like flipping a coin. You'll need regular appointments, usually at the clinic, for check-ups, blood tests, and to receive your treatment. Doctors will closely monitor your health and how your cancer is responding. The duration of your participation will vary depending on your treatment plan and how your body responds. The study team will explain the full schedule of visits and assessments to you in detail.

Potentiella risker och fördelar

Participating in research studies like this means we are hoping to find better ways to treat ovarian cancer. A potential benefit of joining could be receiving a new treatment, sac-TMT, which might keep your cancer from getting worse for longer than current treatments. However, like all medicines, sac-TMT can have side effects, which the study team will discuss with you. There’s also no guarantee that the new treatment will be better or even as good as the standard options. You could also be assigned to the standard care group. It's very important to remember that participating in any clinical trial is entirely voluntary, and you are free to withdraw at any time for any reason without it affecting your usual medical care.

Platser (177)

  • University of Alabama - Birmingham ( Site 0058)
    Verifierat postnummer
    Birmingham, USA· Rekrytering
  • UCSD Moores Cancer Center ( Site 0038)
    Verifierat postnummer
    La Jolla, USA· Rekrytering
  • John Muir Health Cancer Center ( Site 0069)
    Verifierat postnummer
    Walnut Creek, USA· Rekrytering
  • Anschutz Cancer Pavilion ( Site 0049)
    Verifierat postnummer
    Aurora, USA· Rekrytering
  • University of Colorado Health - Highlands Ranch Hospital ( Site 0094)
    Verifierat postnummer
    Highlands Ranch, United States· Rekrytering
  • Mount Sinai Cancer Center ( Site 0029)
    Verifierat postnummer
    Miami Beach, USA· Rekrytering
  • Orlando Health Winnie Palmer Hospital for Women and Babies ( Site 0085)
    Verifierat postnummer
    Orlando, USA· Rekrytering
  • Winship Cancer Institute of Emory University ( Site 0037)
    Verifierat postnummer
    Atlanta, USA· Rekrytering
  • Illinois Cancer Specialists (ICS) ( Site 8009)
    Verifierat postnummer
    Arlington Heights, United States· Rekrytering
  • Parkview Research Center at Parkview Regional Medical Center ( Site 0055)
    Verifierat postnummer
    Fort Wayne, USA· Rekrytering
  • Franciscan Health Indianapolis ( Site 0081)
    Verifierat postnummer
    Indianapolis, USA· Rekrytering
  • Women's Cancer Care ( Site 0018)
    Verifierat postnummer
    Covington, United States· Rekrytering

Vanliga frågor

What is 'advanced ovarian cancer'?

Advanced ovarian cancer means the cancer has spread beyond the ovaries and may have reached other parts of the body.

What is a 'targeted therapy'?

A targeted therapy is a type of medicine that specifically attacks certain parts of cancer cells, aiming to cause less harm to healthy cells.

What is 'maintenance treatment'?

After initial treatment like surgery and chemotherapy, maintenance treatment is given to help keep the cancer from growing, spreading, or coming back.

Kommer jag definitivt att få den nya medicinen?

No, participants are randomly assigned to either receive the new study medicine (with or without bevacizumab) or standard care, such as bevacizumab or observation.

Hur länge skulle jag vara med i studien?

The length of time you'd be involved in the study can vary depending on your treatment plan and how your cancer responds. The doctors will explain this to you.

Hur du får reda på mer

Kostnadsfri nummer

Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.

Intresserad av att delta?

Registrera ditt intresse

Dela dina uppgifter och forskarteamet för "A Clinical Trial of Sac-TMT in People With Non-HRD Positive …" kommer att kontakta dig om du kan vara berättigad. Prata alltid med din läkare innan du går med på att delta.

Diskussion

Gemenskapsdiskussion

Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.